Atomfair

Awaiting product image

Atomfair Tretazicar CB 1954, CB1954 C9H8N4O5

Description Tretazicar (CB 1954) is a nitroaromatic compound with the molecular formula C9H8N4O5and CAS number 17475-67-1 . Its IUPAC name is 5-(aziridin-1-yl)-2,4-dinitrobenzamide . This small molecule is a well-known bioreductive prodrug that has been extensively studied for its potential in cancer therapy , particularly in enzyme-directed prodrug therapy (GDEPT) and antibody-directed enzyme prodrug therapy (ADEPT) . Tretazicar is activated by the enzyme nitroreductase , which converts it into a potent DNA interstrand cross-linking agent , leading to selective cytotoxicity in tumor cells. The compound is supplied as a high-purity solid, suitable for research applications in oncology, pharmacology, and drug development.…

Category:
Brands:

Description

Description

Tretazicar (CB 1954) is a nitroaromatic compound with the molecular formula C9H8N4O5 and CAS number 17475-67-1. Its IUPAC name is 5-(aziridin-1-yl)-2,4-dinitrobenzamide. This small molecule is a well-known bioreductive prodrug that has been extensively studied for its potential in cancer therapy, particularly in enzyme-directed prodrug therapy (GDEPT) and antibody-directed enzyme prodrug therapy (ADEPT). Tretazicar is activated by the enzyme nitroreductase, which converts it into a potent DNA interstrand cross-linking agent, leading to selective cytotoxicity in tumor cells. The compound is supplied as a high-purity solid, suitable for research applications in oncology, pharmacology, and drug development. Store in a cool, dry place, protected from light.

  • CAS No: 17475-67-1
  • Molecular Formula: C9H8N4O5
  • Molecular Weight: 252.18
  • Exact Mass: 252.04946937
  • Monoisotopic Mass: 252.04946937
  • IUPAC Name: 5-(aziridin-1-yl)-2,4-dinitrobenzamide
  • SMILES: C1CN1C2=C(C=C(C(=C2)C(=O)N)[N+](=O)[O-])[N+](=O)[O-]
  • Synonyms: Tretazicar, 21919-05-1, CB 1954, 5-(AZIRIDIN-1-YL)-2,4-DINITROBENZAMIDE, CB1954

Application

Tretazicar (CB 1954) is primarily used in cancer research as a model prodrug for studying enzyme-activated cytotoxicity. It is employed in gene-directed enzyme prodrug therapy (GDEPT) systems, where nitroreductase-expressing cells selectively activate the compound to induce tumor cell death. Researchers also utilize Tretazicar in in vitro and in vivo studies to evaluate its pharmacokinetics, metabolism, and therapeutic potential.

If you are interested or have any questions, please contact us at support@atomfair.com